Day 1
9 June 2010 8am - 5:30pm
Day 2
10 June 2010 8am - 5:30pm
|
|
|
Need a booster for your vaccine business?
Ride on World Vaccine Congress Asia to reach out to the entire Asian vaccine industry!
Lead generation
Meet the leading executives who will be attending our conference and exhibition to explore new vaccine technology & solutions.
Make direct sales
Gain direct access to key decision makers from forward thinking and pro-active companies looking to optimise their vaccine manufacturing processes, pre-clinical, and clinical development.
|
showcase your products
|
|
enjoy maximum exposure
|
Establish yourself
Deepen your relationship with existing clients and make an impact on your potential clients – make sure your company branding is at the
forefront!
Exclusive positioning
We will be limiting the number of exhibitors for this event to ensure that our exhibitors have maximum exposure and are able to reach out effectively to their buyers or partners at the event.
|
Our sponsors..
| Gold sponsor: |
|
|
| GE Healthcare provides life science research products and biopharmaceutical manufacturing technologies. Over 90% of the current biopharmaceuticals therapies on the market are manufactured utilizing chromatography media from GE Healthcare. In addition, our service organization helps you improve productivity and reduce costs associated with the upkeep of laboratory and manufacturing equipment. |
| Gold sponsor: |
|
|
|
The life sciences industry is both driven and united by its need for speed to market, product reliability and economics. Pall’s leading edge filtration, separation and purification technologies and services play an essential and pivotal role in this industry’s ability to achieve these goals. In the laboratory, Pall products help to facilitate the drug discovery and development process to get innovative drugs to the market faster. In Biopharmaceuticals, Pall filtration, chromatography, sampling, monitoring and quality assurance products, together with technical services in validation, assays and process optimization are applicable to laboratory and pilot-scale development, aseptic processing, biologicals, bioprocessing, fermentation and downstream processing.
|
|
Gold Sponsor:
|
|
|
|
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions".
Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approximately 2,400 people, and in 2009 earned sales revenue of 401.2 million euros.
|
|
Silver:
|
| Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world's challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 6,100 employees in 47 countries worldwide. |
|
Session:
|
| Medicago is a Canadian clinical stage company committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particles and manufacturing technologies. We develop vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology could offer advantages of speed and cost over competitive technologies by delivering a vaccine in about a month after the identification of pandemic strains. |
|
Session:
|
| NNE Pharmaplan is a Pharmaceutical Engineering company using unique business and process understanding to deliver complete services and solutions. With more than 80 years of industry focus and 20 global locations, we provide competitive advantages to our clients when we establish and improve manufacturing. We are passionate and committed about client success and proud of our long-term relationships. www.nnepharmaplan.com |
|
Innovative Showcase:
|
| AVIR Green Hills Biotechnology is a biopharmaceutical company based in Vienna, Austria. The company uses its know-how in virology to develop and commercialize innovative products that offer cost-effective treatment for a wide range of diseases. The products under development by AVIR Green Hills Biotechnology are unique therapies against viral infectious diseases and cancer with the aim to significantly improve health and the quality of life of human beings. |
|
Innovative Showcase:
|
|
Immune Targeting Systems is a London based biotech company developing synthetic vaccines for mutating viruses underpinned by its DepoVaccine and High Density Antigen identification technology platforms.
ITS’s lead program is a synthetic universal influenza vaccine targeting all potential seasonal and pandemic flu strains. Phase-I is expected to commence in Q3-2010 and pharmtox studies with GMP vaccine are in progress.
This next generation broadly applicable T-cell vaccine platform encompasses the DepoVaccine and High Density Antigen identification technology platforms. DepoVaccines deliver high density antigens to the immune system and promote a vaccine depot at the injection site. This depot promotes potent, durable and recallable antiviral T-cell immunity without adjuvants.
Vaccine design specifically address key aspects of human immunological-vaccine performance required for clinical success; (i) vaccine responder frequency >95%, (ii) breadth of response, (iii) magnitude of response, & (iv) multi-re-use capability afforded by synthetic long-peptides.
HD-Antigens are naturally occurring viral peptides (35 amino acids) which are highly conserved across all viral strains and contain high density clusters of CD4 T-Helper and CD8 Cytotoxic T-Lymphocyte epitopes ensuring broad human population coverage. HD-Antigens are conjugated to a fluorocarbon vector. Each vaccine contains multiple (6-8) HD-antigens as a freeze dried thermostable nanoparticle based formulation. Candidates for Hepatitis-B & C, HIV, HPV-cancer await development funding or partners.
|
|
Innovative Showcase:
|
|
Pevion Biotech develops efficient and safe vaccines based on its proprietary virosome technology platform. By combining established technological processes with innovative concepts, the company promotes novel vaccine candidates from research into clinical testing. Two vaccines which rely on Pevion Biotech´s technology are registered and already on the market. To increase and make the most of the combined scientific expertise and to enable further product development, Pevion Biotech collaborates with biotech companies, universities and research institutes. The company´s pipeline includes vaccines against breast cancer, influenza, candidiasis and RSV. Pevion Biotech has the most complete patent portfolio covering all aspects and applications of the virosome-based technology platforms. Furthermore, the company has filed patent applications to protect each of the project specific antigens. The portfolio consists of thirteen patent families, protecting not only the use of virosomes as adjuvant/carrier for vaccines but also their use as drug delivery vehicle. Located in Bern, Switzerland, the company currently has a highly qualified staff of 26 research fellows.
|
|
Exhibitor:
|
| BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The company is dedicated to improving people’s health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. |
|
Exhibitor:
|
| PAA Laboratories is a leading manufacturer of cell culture products, such as sera, media and reagents. The GMP compliant manufacturing site in Europe houses the most modern powder media production unit, worldwide. State-of-the-art production facilities in America and Australia, sales subsidiaries and more than 50 distributors provide the highest level of customer service. |
|
Exhibitor:
|
SAFC® is committed to providing consistent, secure solutions that can help global companies deliver vaccines to market quickly and efficiently. Scientists throughout the world rely upon SAFC’s unique upstream/downstream expertise and high-quality raw materials to resolve development issues, develop risk mitigation strategies and shorten timelines in their vaccine programs.
More information at www.safcglobal.com/vaccines |
|
Exhibitor:
|
| Synbiosis designs and develops market-leading automated inhibition zone measurement and colony counting systems. The company’s latest ProtoCOL 2 system can be configured to increase productivity in any GMP vaccine manufacturing facility and generates accurate, reproducible potency analysis of flu vaccines on SRD assay plates and bacterial vaccines tested by plate-based colony counts and inhibition zone analysis. |
|
|
|
|
|
